Furthermore, treatment with the CXCR2 antagonist SB225002 reduced the infiltration of CXCR2+ neutrophils to the heart after MI (≈2-fold) and neutrophil depletion with an anti-Ly6G antibody improved the recovery after MI at ZT1335 (Figure 2C). The gene discussed is CXCR2; the disease is myocardial infarction.